Company / R&D Expense
Avidity Biosciences, Inc. R&D Expense History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$559.2M
FY2025
5-year range
$101.2M / $559.2M
FY2021-FY2025
Trend
+84.2%
vs FY2024
Sector context
#31 of 210
Health Care
What the data says
Avidity Biosciences, Inc.'s r&d expense of $559M is higher than 85% of companies in the Health Care sector (FY2025). R&D Expense has increased for 7 consecutive years, from $8M in FY2018 to $559M in FY2025.
Based on SEC 10-K filings.
$559M in FY2025 with a 5-year CAGR of +71.6%. Top quartile in the Health Care sector.
Improved from $191M to $559M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +54.9%
- 5-Year CAGR
- +71.6%
- 10-Year CAGR
- -
Sector benchmark
Top 15% in Health CareTop 15% of 210This company $559.2M Sector average $644.1M
▼
-13.2% below sector average
Key checks
Key Insights
- Avidity Biosciences, Inc.'s r&d expense has grown for 7 consecutive years.
- 5-year CAGR of +71.6%, indicating consistent growth.
- In FY2025, r&d expense increased 84.2% year-over-year.
- Ranks #31 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $559.2M | +84.2% |
| FY2024 | $303.6M | +59.0% |
| FY2023 | $191.0M | +27.0% |
| FY2022 | $150.4M | +48.6% |
| FY2021 | $101.2M | +169.1% |
| FY2020 | $37.6M | +158.6% |
| FY2019 | $14.5M | +72.3% |
| FY2018 | $8.4M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026